KTTA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KTTA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pretax income is the income that a company earns before paying income taxes. Pasithea Therapeutics's pretax income for the three months ended in Mar. 2024 was $-3.86 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-16.10 Mil. Pasithea Therapeutics's pretax margin was %.
During the past 4 years, Pasithea Therapeutics's highest Pretax Margin was -14493.33%. The lowest was -14493.33%. And the median was -14493.33%.
The historical data trend for Pasithea Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pasithea Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Pre-Tax Income | - | -2.17 | -11.73 | -15.51 |
Pasithea Therapeutics Quarterly Data | |||||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Pre-Tax Income | Get a 7-Day Free Trial | -3.27 | -3.60 | -3.61 | -5.03 | -3.86 |
For the Biotechnology subindustry, Pasithea Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Pasithea Therapeutics's Pre-Tax Income falls into.
This is the income that a company earns before paying income taxes.
Pasithea Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pretax Income | = | Operating Income | + | Non Operating Income | + | Interest Expense | + | Interest Income | + | Other |
= | -15.979 | + | 0.056 | + | 0 | + | 0.415 | + | 1.7763568394003E-15 | |
= | -15.51 |
Pasithea Therapeutics's Pretax Income for the quarter that ended in Mar. 2024 is calculated as
Pretax Income | = | Operating Income | + | Non Operating Income | + | Interest Expense | + | Interest Income | + | Other |
= | -4.041 | + | 0.027 | + | 0 | + | 0.153 | + | 0 | |
= | -3.86 |
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pasithea Therapeutics (NAS:KTTA) Pre-Tax Income Explanation
Pasithea Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
Pretax Margin | = | Pretax Income | / | Revenue |
= | -3.861 | / | 0 | |
= | % |
During the past 4 years, Pasithea Therapeutics's highest Pretax Margin was -14493.33%. The lowest was -14493.33%. And the median was -14493.33%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Pasithea Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Graeme Martin Currie | officer: Chief Development Officer | 51 BARBAREE WAY, TIBURON CA 94920 |
Lawrence Steinman | director | 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121 |
Bradford Manning | 10 percent owner | C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902 |
Paul B Manning | 10 percent owner | 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902 |
Tiger Lily Capital, Llc | 10 percent owner | C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902 |
Pd Joint Holdings, Llc Series 2016-a | 10 percent owner | C/O TIGER LILY CAPITAL LLC, 200 GARRETT STREET, SUITE O, CHARLOTTESVILLE VA 22902 |
Elderhill Corp | other: Member of 10% owner group | C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T IN5 |
Concord Ip2 Ltd. | other: Member of 10% owner group | C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5 |
David Delaney | other: Member of 10% owner group | C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5 |
Eric Shahinian | other: Member of 10% owner group | 350 PARK AVE, 13TH FL, NEW YORK NY 10022 |
Alfred J Novak | director | 325 NE 6TH ST, BOCA RATON FL 33432 |
Camac Partners, Llc | other: Member of 10% owner group | 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022 |
Camac Capital, Llc | other: Member of 10% owner group | 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022 |
Camac Fund, Lp | other: Member of 10% owner group | CAMAC CAPITAL, LLC, 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022 |
Leonite Capital Llc | other: Member of 10% owner group | 1 HILLCREST CENTER DR., SUITE 232, SPRING VALLEY NY 10977 |
From GuruFocus
By GlobeNewswire • 12-28-2023
By Value_Insider Value_Insider • 12-06-2022
By PurpleRose PurpleRose • 08-02-2022
By Business Wire Business Wire • 08-24-2022
By Value_Insider Value_Insider • 12-14-2022
By sperokesalga sperokesalga • 02-23-2023
By sperokesalga sperokesalga • 06-01-2023
By sperokesalga sperokesalga • 06-06-2023
By sperokesalga sperokesalga • 05-03-2023
By PurpleRose PurpleRose • 07-14-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.